NCT01714739 arm group ebbb522daa43864a88f3d7007f4c9614 [clinicaltrials_resource:NCT01714739/arm-group/ebbb522daa43864a88f3d7007f4c9614]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01714739 arm group ebbb522daa43864a88f3d7007f4c9614 [clinicaltrials_resource:NCT01714739/arm-group/ebbb522daa43864a88f3d7007f4c9614]
Bio2RDF identifier
NCT01714739/arm-group/ebbb522daa43864a88f3d7007f4c9614
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... bb522daa43864a88f3d7007f4c9614
description [clinicaltrials_vocabulary:description]
Lirilumab 0.3 mg/kg solution i ...... 96 weeks depending on response
identifier
clinicaltrials_resource:NCT01714739/arm-group/ebbb522daa43864a88f3d7007f4c9614
title
NCT01714739 arm group ebbb522daa43864a88f3d7007f4c9614
@en
type
label
NCT01714739 arm group ebbb522d ...... b522daa43864a88f3d7007f4c9614]
@en